Evidence in Primary Prevention of Type 2 Diabetes Mellitus—What It Means for Primary Prevention of Type 2 Diabetes Mellitus Epidemic in Papua New Guinea — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Evidence in Primary Prevention of Type 2 Diabetes Mellitus—What It Means for Primary Prevention of Type 2 Diabetes Mellitus Epidemic in Papua New Guinea
Department of General Internal Medicine, Port Moresby General Hospital, Port Moresby, Papua New Guinea
1 Department of General Internal Medicine, Port Moresby General Hospital, Port Moresby, Papua New Guinea
Type 2 diabetes is in epidemic proportion in Papua New Guinea. Although many people are at high-risk of developing diabetes, there is no diabetes prevention policy and services in Papua New Guinea to address this problem. A literature search was carried out to assess the available evidence in the primary prevention of type 2 diabetes mellitus among the population with pre-diabetes. The result show s that the primary preventative studies conducted on lifestyle modification and the use of metformin in prediabetes patients reduced overt type 2 diabetes mellitus. The application of the evidence in the prevention of the type 2 diabetes epidemic in Papua New Guinea, driven by a policy is feasible to address the diabetes epidemic.
World Health Organization. Diabetes Program. https://www.who.int/news-room/fact-sheets/detail/diabetes
Wild, S., Roglic, G., Green, A., Sicree, R. and King, H. (2004) Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030. Diabetes Care, 27, 1047-1053. https://doi.org/10.2337/diacare.27.5.1047
Papua New Guinea National Department of Health (2010) Annual Report (Unpublished). Government Printers, Waigani.
Papua New Guinea National Department of Health (2009) Diabetes Survey (Unpublished). Government Printers, Waigani.
Pulford, J., Rarau, P., Vengiau, G., Gouda, H., Phuanukoonnon, S. and the Scientific Advisory Board (2015) Non-Communicable Diseases and Associated Risk Factors in the Hiri, Asaro and Karkar Integrated Health and Demographic Surveillance Sites. Papua New Guinea Institute of Medical Research, Goroka. https://www.pngimr.org.pg/wp-content/uploads/2019/05/Report-on-Non-Communicable-diseases-associated-risk-factors-in-the-Hiri-Karkar-and-Asaro-integrated-health-and-demographic-surveillance-sites.pdf
Division of Internal Medicine, Port Moresby General Hospital (2011) Annual Audit Report (Unpublished).
Engelgau, M.M., Aubert, R.E., Thompson, T.J. and Herman, W.H. (1995) Screening for NIDDM in Non-Pregnant Adults: A Review of Principles, Screening Tests, and Recommendations. Diabetes Care, 18, 1606-1618. https://doi.org/10.2337/diacare.18.12.1606
Khunti, K. and Davies, M. (2012) Should We Screen for Type 2 Diabetes: Yes. BMJ, 345, e4514. https://doi.org/10.1136/bmj.e4514
Goyder, E., Irwig, L. and Payne, N. (2012) Should We Screen for Type 2 Diabetes? No. BMJ, 345, E4516. https://doi.org/10.1136/bmj.e4516
World Health Organization, International Diabetes Federation (2006) Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. A Report of a WHO/IDF Consultation. https://www.who.int/diabetes
Sartor, G., Schersten, B., Carlstrom, S., et al. (1980) Ten-Year Follow-Up of Subjects with Impaired Glucose Tolerance. Prevention of Diabetes by Tolbutamide and Diet Regulation. Diabetes, 29, 41-49. https://doi.org/10.2337/diabetes.29.1.41
Eriksson, K.F. and Lindgarde, F. (1998) No Excess 12-Year Mortality in Men with Impaired Glucose Tolerance Who Participated in the Malmo Preventive Trial with Diet and Exercise. Diabetologia, 41, 1010-1016. https://doi.org/10.1007/s001250051024
Pan, X.R., Li, G.W., Hu, Y.H., Wang, J.X., Yang, W.Y., An, Z.X., et al. (1997) Effects of Diet and Exercise in Preventing NIDDM in People with Impaired Glucose Tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care, 20, 537-544. https://doi.org/10.2337/diacare.20.4.537
Tuomilehto, J., Lindstrőm, J., Erisson, J.G., Valle, T.T., Hämäläinen, H., Ilanne-Parikka, P., et al. (2001) Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance. The New England Journal of Medicine, 344, 1343-1350. https://doi.org/10.1056/NEJM200105033441801
Knowler, W.C., Connor, E.B., Fowler, S.E., Hamman, R.F., Lachin, J.F., Walker, E.A., et al. (2002) Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. The New England Journal of Medicine, 346, 393-403. https://doi.org/10.1056/NEJMoa012512
Ramachandran, A., Snehalatha, C., Mary, S., et al. (2006) Indian Diabetes Prevention Program (IDPP). The Indian Diabetes Prevention Program Shows That Lifestyle Modification and Metformin Prevent Type 2 Diabetes in Asian Indian Subjects with Impaired Glucose Tolerance (IDPP-1). Diabetologia, 49, 289-297. https://doi.org/10.1007/s00125-005-0097-z
Chiasson, J.L., Josse, R.G., Gomis, R., et al. (2002) STOP-NIDDM Trial Research Group: Acarbose for Prevention of Type 2 Diabetes Mellitus: The STOP NIDDM Randomised Trial. The Lancet, 359, 2072-2077. https://doi.org/10.1016/S0140-6736(02)08905-5
Torgerson, J.S., Hauptman, J., Boldrin, M.N. and Sjostrom, L. (2004) Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A Randomized Study of Orlistat as an Adjunct to Lifestyle Changes for the Prevention of Type 2 Diabetes in Obese Patients. Diabetes Care, 27, 151-161. https://doi.org/10.2337/diacare.27.1.155
Gerstein, H.C., Yusuf, S., Boxch, J., et al. (2006) DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators: Effect of Rosiglitazone on the Frequency of Diabetes in Patients with Impaired Glucose Tolerance or Impaired Fasting Glucose: A Randomized Controlled Trial. The Lancet, 368, 1096-105. https://doi.org/10.1016/S0140-6736(06)69420-8
Buchanan, T.A., Xiang, A.H., Peters, R.K., et al. (2002) Preservation of Pancreatic Beta-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women. Diabetes, 51, 2796-2803. https://doi.org/10.2337/diabetes.51.9.2796
DeFronzo, R.A., Tripathy, D., Schwenke, D.C., Banerji, M., Bray, G.A., Buchanan, T.A., Clement, S.C., Henry, R.R., Hodis, H.N., Kitabchi, A.E. and ACT NOW Study Group (2011) Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance. The New England Journal of Medicine, 364, 1104-1115. https://doi.org/10.1056/NEJMoa1010949
Nathan, D.M., Davidson, M., DeFronzo, R.A., et al. (2007) Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for Care. A Consensus Statement from the American Diabetes Association. Diabetes Care, 30, 753-759. https://doi.org/10.2337/dc07-9920
Stellefson, M., Dipnarine, K. and Stopka, C. (2013) The Chronic Care Model and Diabetes Management in US Primary Care Settings: A Systematic Review. Preventing Chronic Disease, 10, Article ID: 120180. https://doi.org/10.5888/pcd10.120180
Ahead of Blue Monday. Global Risk Development. https://www.grouprisk.org.uk/2019/01/18/ahead-of-blue-monday-research-from-grid-less-than-a-fifth-of-employers-proactively-manage-stress-and-mental-health-issues
WHO Regional Office for Europe (2015) Using Price Policies to Promote Healthier Diets. WHO Regional Office for Europe, Copenhagen.
Veerman, J.L., Sacks, G., Antonopoulos, N. and Martin, J. (2016) The Impact of a Tax on Sugar-Sweetened Beverages on Health and Health Care Costs: A Modelling Study. PLoS ONE, 11, e0151460. http://journals.plos.org/plosone/article?id=10.1371 https://doi.org/10.1371/journal.pone.0151460
(2016) Sugary Drinks Tax—The Great Debate. Sugar Nutrition Resource Centre. https://www.sugarnutritionresource.org/news-articles/sugary-drinks-tax-the-great-debate